#1 Clinical Trials Search in Europe

Study Comparing Relatlimab-Nivolumab Combination with Regorafenib or Trifluridine-Tipiracil for Patients with Advanced Metastatic Colorectal Cancer

1 1 1 1

What is this study about?

This clinical trial is focused on studying treatments for Metastatic Colorectal Cancer, a type of cancer that has spread from the colon or rectum to other parts of the body. The study is comparing the effectiveness of a new treatment combination called Relatlimab + Nivolumab with two existing treatments: Regorafenib and a combination of Trifluridine + Tipiracil, also known as TAS-102. The purpose of the study is to see how well these treatments work for patients who have already tried other therapies.

Participants in the study will be randomly assigned to receive either the new treatment combination or one of the existing treatments. The new treatment, Relatlimab + Nivolumab, is given as an infusion, which means it is administered directly into the bloodstream through a vein. The existing treatments, Regorafenib and TAS-102, are taken as tablets by mouth. The study will monitor participants over a period to assess the impact of these treatments on their cancer.

The trial aims to gather information on how these treatments affect overall survival, which is the length of time patients live after starting the treatment. It will also look at other factors such as the response of the cancer to the treatment and any side effects experienced by participants. This information will help determine the best treatment options for patients with Metastatic Colorectal Cancer who have limited options after previous treatments. The study is expected to continue until 2028.

1 enrollment

Upon joining the study, eligibility is confirmed based on specific criteria, including a diagnosis of metastatic colorectal cancer and previous treatment history.

Documentation of tumor characteristics and KRAS mutation status is required.

2 randomization

Participants are randomly assigned to receive either the relatlimab-nivolumab combination or one of the standard care therapies: regorafenib or TAS-102 (trifluridine and tipiracil).

3 treatment administration

For those receiving the relatlimab-nivolumab combination, the medication is administered through an intravenous infusion.

Participants assigned to regorafenib take 40 mg film-coated tablets orally.

Participants assigned to TAS-102 take either 20 mg/8.19 mg or 15 mg/6.14 mg film-coated tablets orally.

4 treatment schedule

The treatment continues as per the study protocol, with regular monitoring and assessments to evaluate the response to the treatment.

5 monitoring and assessments

Regular assessments are conducted to monitor the disease progression and response to treatment.

These assessments include imaging studies and laboratory tests to evaluate overall health and treatment effects.

6 completion

The study is estimated to conclude by May 31, 2028, with ongoing evaluations of overall survival and other health outcomes.

Who Can Join the Study?

  • You must have metastatic colorectal cancer, which means the cancer has spread to other parts of the body.
  • Your cancer must be confirmed as adenocarcinoma, a type of cancer that forms in mucus-secreting glands.
  • The cancer must be metastatic or recurrent and cannot be removed by surgery at the time of joining the study.
  • You must have tried standard cancer treatments and either the cancer got worse during or within about 3 months after the last treatment, or you couldn’t tolerate the treatments due to significant side effects.
  • You need to have enough tumor tissue available for testing and meet the study’s requirements for PD-L1 expression, a protein that can affect how the immune system responds to cancer.
  • Your KRAS mutation status must be known from previous tests. This is a specific gene change that can affect cancer growth.
  • You must have cancer that can be measured according to specific guidelines. If the only measurable cancer is in an area that was previously treated with radiation, it must show clear signs of getting worse and be measurable.
  • Both men and women can participate in the study.
  • The study includes people who might be considered vulnerable, meaning they may need extra protection or care.

Who Cannot Join the Study?

  • Patients who have a different type of cancer other than metastatic colorectal cancer cannot participate. Metastatic means the cancer has spread to other parts of the body.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who are not able to follow the study procedures or comply with the study requirements cannot participate.
  • Patients who have certain medical conditions that might interfere with the study treatment cannot participate.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients who have received certain treatments or medications that might interfere with the study cannot participate.
  • Patients who have a history of severe allergic reactions to the study drugs cannot participate.
  • Patients who are part of a vulnerable population, such as those unable to give informed consent, cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Centr Georges Francois Leclerc Dijon France
Azienda Ospedaliera Universitaria Universita’ Degli Studi Della Campania Luigi Vanvitelli Naples Italy
Haematologisch Onkologische Praxis Eppendorf Hamburg Germany
Universitaetsklinikum Heidelberg AöR Heidelberg Germany
Centre Hospitalier Universitaire De Bordeaux Bordeaux France
Katholieke Universiteit te Leuven Leuven Belgium

Other Sites

Site Name City Country Status
Krankenhaus Nordwest GmbH Frankfurt Germany
Istituto Oncologico Veneto Padua Italy
Hopital Saint Antoine Paris France
Netherlands Cancer Institute Amsterdam The Netherlands
Hospital Foch Suresnes France
IRCCS Istituto Nazionale Tumori Fondazione Pascale Naples Italy
Hospital Universitario 12 De Octubre Madrid Spain
ARNAS Garibaldi Di Catania Catania Italy
Az Maria Middelares Gent Gent Belgium
SCRI CCCIT Ges.m.b.H. Salzburg Austria
Europejskie Centrum Zdrowia Otwock Sp. z o.o. Otwock Poland
IHFB Cognacq Jay Levallois-Perret France
Region Skane Skanes Universitetssjukhus Lund Sweden
Hospital Unviersitario Miguel Servet Zaragoza Spain
Virgen del Rocío University Hospital Sevilla Spain
ASST Grande Ospedale Metropolitano Niguarda Milan Italy
Hospital Clinic De Barcelona Barcelona Spain
Charite Universitaetsmedizin Berlin KöR Berlin Germany
Fakultni Nemocnice Hradec Kralove Novy Hradec Kralove Czechia
Karolinska University Hospital Solna Sweden
IRCCS Ospedale Policlinico San Martino Genoa Italy
Pratia S.A. Skorzewo Poland
Sankt Gorans Sjukhus Stockholm Sweden
University Hospital Olomouc Olomouc Czechia
Queen Silvia Childrens Hospital – Sahlgrenska University Hospital – Vaestra Goetalandsregionen Gothenburg Sweden
Fondazione I.R.C.C.S. Istituto Neurologico Besta Milan Italy
University Hospital Ostrava Ostrava Czechia
Centre Francois Baclesse Caen France
Czpqjghnf Uealugmdfrraip Ssnhsvnad Woluwe-Saint-Lambert Belgium
Kjsbhjmbuhsry Rzjguuwkpk Guih Reutlingen Germany
Cfoemq Lbgv Btplos Lyon France
Useudehleoqwqmjgihrgy Ecaat Aid Essen Germany
Mnvtbcklv svtiiz Horovice Czechia
Fbnktake ntkecwbiz Muppc a Hzveyvy Prague Czechia
Uvpaczw Usllumqhtw Hbuolofq Uppsala Sweden
Pzurpmcze Irvjuwfb Mtvyprbn Mgkrmyvgfxgk Svhwb Wzrtbiujwtft I Afxgeshhktrlc Warsaw Poland
Noorcbum Iyulnang Oymxucplm Ijx Muliy Sujwwfsvkptwzhzsrdfkykfqqhhl Iwoqmccw Bsrjjubr Cracow Poland
Kmumaitw dmk Ufhgxkzfefsr Mafigboe Alq Munich Germany
Aqshkmf Uuo Ifqcg Da Rzfjxs Ehafrn Reggio Emilia Italy
Iqbjseig Ccscav Dynnujsnoxbnxcfoq L'hospitalet De Llobregat Spain
Fivlreieo Psco Lv Itueagsjiwlpk Bvqrvisst Dir Hwzcybrk Urdnozsmmdqgx Lq Pre Madrid Spain
Hjknqztw Vetq dhzfdpwj Barcelona Spain
Hpzvsrpi Urksypsgpqogr df A Cstcbp A Coruna Galicia Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Austria Austria
Not recruiting
31.03.2022
Belgium Belgium
Not recruiting
31.03.2022
Czechia Czechia
Not recruiting
31.03.2022
France France
Not recruiting
31.03.2022
Germany Germany
Not recruiting
31.03.2022
Italy Italy
Not recruiting
31.03.2022
Poland Poland
Not recruiting
31.03.2022
Spain Spain
Not recruiting
31.03.2022
Sweden Sweden
Not recruiting
31.03.2022
The Netherlands The Netherlands
Not recruiting
31.03.2022

Trial locations

Investigated drugs:

Relatlimab-nivolumab Fixed-dose Combination is a combination of two medications used together to help the immune system fight cancer. Relatlimab and nivolumab are both types of drugs called immune checkpoint inhibitors. They work by blocking certain proteins on cancer cells, which helps the immune system recognize and attack the cancer.

Regorafenib is a medication used to treat certain types of cancer by blocking proteins that help cancer cells grow. It is often used when other treatments have not been successful. Regorafenib works by slowing down the growth and spread of cancer cells.

Trifluridine + Tipiracil (TAS-102) is a combination of two drugs used to treat cancer. Trifluridine is a type of chemotherapy that interferes with the DNA of cancer cells, preventing them from growing and dividing. Tipiracil helps increase the effectiveness of trifluridine by preventing its breakdown in the body. Together, they work to slow down the growth of cancer cells.

Investigated diseases:

Metastatic Colorectal Cancer – This is a type of cancer that begins in the colon or rectum and has spread to other parts of the body. It often progresses through stages, starting in the lining of the colon or rectum and potentially moving to nearby lymph nodes and distant organs, such as the liver or lungs. The disease can cause symptoms like changes in bowel habits, abdominal pain, and weight loss. As it advances, it may lead to more severe symptoms depending on the organs affected. The progression can vary greatly among individuals, with some experiencing rapid spread while others have a slower course. Understanding the specific pathways and mechanisms of spread is crucial for managing the disease.

Trial ID:
2023-503797-21-00
Protocol code:
CA224-123
NCT ID:
NCT05328908
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study of FOLFOX or FOLFIRI chemotherapy with fruquintinib or bevacizumab as second-line treatment for patients with metastatic colorectal cancer

    Recruiting

    1 1 1
    Investigated drugs:
    France

  • Treatment with trastuzumab deruxtecan, capecitabine and bevacizumab for patients with HER2-positive metastatic colorectal cancer

    Recruiting

    1 1 1
    Investigated drugs:
    France Germany Italy Spain